Qatar Universal Diabetes Outcomes (QUDOS) Study

NCT02660476 | Terminated DMC

• 1 other identifier: JIRB: 14-0032. MRC: #14461/14
• Study Type: observational
• Target: 475
• Locations: 1 country
• Sites: 1

Brief Summary

QUDOS is a cross-sectional population study aiming to answer key questions about diabetes and its complications in Qatar as well as identify factors associated with the development and progression of diabetes complications.

Conditions

Diabetes Mellitus; Type 2 Diabetes Mellitus

Keywords

Diet; Middle East and North Africa country; Health; Complication; Cardiovascular disease; Obesity; Stress; Obstructive Sleep Apnoea (OSA)

Outcome Measures

Primary Outcomes (1)

• Diabetes Complications (Nephropathy, Neuropathy, Retinopathy)

  Our primary analyses will be conducted to explore the potential cross-sectional relationships amongst proposed factors related to type 2 diabetes complications

  Baseline (Cross-Sectional)

Secondary Outcomes (3)

• Mental Health

  Baseline (Cross-Sectional)

• Sleep and sleep related breathing disorders

  Baseline (Cross-Sectional)

• Physical activity

  Baseline (Cross-Sectional)

Study Arms (2)

QUDOS 1

Aims to recruit 1,700 diabetic patients (including 200 with type 1 diabetes mellitus (independent of healthcare setting)) attending the hospitals and primary care

QUDOS 2

To further characterise 500 patients, from the total 1500 patients with T2DM recruited in QUDOS 1, who accept to continue with QUDOS 2 (a more detailed study and assessment).

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Adult patients 18-70 years old with diabetes, who are a resident in Qatar or born in one of the MENA countries with family originating from MENA countries, will be recruited from one of the following sites: * Primary health care centers * Hamad General Hospital * Al-Wakra Hospital * Al-Khor Hospital

You may qualify if:

• Type 1 and Type 2 diabetes mellitus;
• Male or Female;
• Resident in Qatar;
• MENA birthplace and family origin;
• years old;
• Capable to give informed consent and complete the study.

You may not qualify if:

• \. Known pregnancy or planning pregnancy during the duration of study; 2. Congenital disorders; 3. Terminal illness; 4. Enrolled in a clinical trial involving medication; 5. Uncontrolled mental illness preventing participation; 6. Those who have already experienced a definitive microvascular complication:
• i. End-stage renal disease; ii. Major amputation; iii. Blindness.

Sponsors & Collaborators

• Weill Cornell Medical College in Qatar: lead
• Hamad Medical Corporation: collaborator

Study Sites (1)

Weill Cornell Medicine Qatar

Doha, Qatar

Location

Biospecimen

Retention: SAMPLES WITH DNA

Blood, urine, saliva and stool samples

MeSH Terms

Conditions

Diabetes Mellitus; Diabetes Mellitus, Type 2; Cardiovascular Diseases; Obesity; Sleep Apnea, Obstructive

Condition Hierarchy (Ancestors)

Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases; Overweight; Overnutrition; Nutrition Disorders; Body Weight; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Sleep Apnea Syndromes; Apnea; Respiration Disorders; Respiratory Tract Diseases; Sleep Disorders, Intrinsic; Dyssomnias; Sleep Wake Disorders; Nervous System Diseases

Study Officials

• Shahrad Taheri, PhD

  Weill Cornell Medical College in Qatar

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 20, 2015
• First Posted: January 21, 2016
• Study Start: October 1, 2014
• Primary Completion: June 1, 2023
• Study Completion: June 1, 2023
• Last Updated: June 22, 2023

Record last verified: 2023-06

Locations

QA (1)